Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > ORGANIZATION
ORGANIZATION
- Wholesale Industry FTC Calls for Freeze on Efforts by Wholesalers to Refuse Free Services to Customers Due to Sharp Reactions from Some Pharmacies
September 4, 2013
- Min-Iren to Suspend Use of Diovan at 143 Member Hospitals
August 30, 2013
- JMA, PhRMA to Cosponsor Symposium on National Health Insurance System in September
August 29, 2013
- Insulin Treatment Improves Patients’ QOL, Marital Relationship: Healthy Japan 21 Promotion Forum, Sanofi
August 23, 2013
- Stakeholders Should Discuss Novartis’ Responsibility in the Promotion of Diovan, Large Sales: JMA Vice President
August 19, 2013
- Japanese Wholesalers Fill Role of Social Infrastructure: JPWA Report
August 14, 2013
- JMA Establishes Pharmaceutical Affairs Section to Strengthen Engagement with Generic Drug and Distribution Issues
August 9, 2013
- Kenporen Report Recommends Reference to Measures Taken in UK, France to Further Promote Use of Generics in Japan
August 7, 2013
- ICH to Facilitate Participation of Regulatory Authorities from Non-ICH Regions in Future Activities
July 30, 2013
- Average Cost of Domestic Development Was 48.4 Billion Yen per Drug from 2000-2008: OPIR
July 29, 2013
- Red Cross Hospitals to Share Information on Drug Discount Rates
July 29, 2013
- EFPIA and PhRMA Announce Joint “Principles for Responsible Clinical Trial Data Sharing”
July 26, 2013
- SCJ to Discuss Preventive Measures for Misconduct in Science Research
July 24, 2013
- NPO J-CLEAR Says Diovan Data Manipulated Possibly Outside of Endpoint Committee
July 24, 2013
- JPMA Calls on TPP Member States to Make Drug Pricing Process Transparent
July 22, 2013
- FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
- JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
- Pharmaceutical-Related Companies Should Report Business Results to CSIMC: JMARI Working Paper
July 11, 2013
- Product Names Changed for 10% of New Drugs after NDA Filings: OPIR Survey
July 8, 2013
- JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…